Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XmAb20717 in Advanced Gynecological Malignancies and mCRPC
NCT05032040Phase 2Active, not recruiting
- Sponsor
- Xencor
- Start
- Jul 2022
- Primary completion
- Oct 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vudalimab in ovarian cancer, endometrial cancer (EC), primary peritoneal cancer (PPC), Cervical Cancer (CC), metastatic castration-resistant prostate cancer (mCRPC), sponsored by Xencor. Started Jul 2022; status: active, not recruiting.
02
Drugs
vudalimab
03
Conditions
ovarian cancerendometrial cancer (EC)primary peritoneal cancer (PPC)Cervical Cancer (CC)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05032040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05032040.